Welcome to our dedicated page for Sohm news (Ticker: SHMN), a resource for investors and traders seeking the latest updates and insights on Sohm stock.
SOHM Inc (SHMN) delivers innovative solutions at the intersection of generic pharmaceuticals and advanced gene editing. This news hub provides investors and industry observers with timely updates on the company’s financial developments, research milestones, and strategic initiatives.
Access authoritative reports on earnings announcements, regulatory filings, and technology advancements like the ABBIE genome editing system. Stay informed about partnerships with leading institutions and progress in CAR-T cell therapy applications.
Our curated collection features press releases detailing manufacturing expansions, cosmeceutical product launches, and biotech collaborations. Discover updates on patent approvals, clinical trial developments, and market expansion strategies.
Bookmark this page for streamlined access to verified information about SHMN’s dual focus areas. Check regularly for new insights into how SOHM Inc navigates the evolving biopharmaceutical landscape through its integrated business model.
SOHM, Inc. (OTC PINK: SHMN) announced an exclusive distribution agreement with Stallion Laboratories Pvt. Ltd. to launch Levetiracetam, a medication for treating epilepsy. Levetiracetam, an FDA-approved anticonvulsant, will be manufactured in Ahmedabad, India, and distributed under SOHM's label. The product is anticipated to generate annual revenues between US$3-5 million, aiming for a 5-10% market share over the coming months. The global antiepileptic drug market is projected to grow at a CAGR of 3.9% from 2021 to 2031, driven by rising epilepsy prevalence. The launch is expected within two months, offering a new treatment option that is particularly beneficial for older adults with dementia.
FAQ
What is the current stock price of Sohm (SHMN)?
What is the market cap of Sohm (SHMN)?
